Repligen assumes no obligation to update forward-looking information in this press release to update or with respect to the announcements contained herein.. This press release contains forward-looking statements pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 , as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release that are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management ‘s strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, are forward-looking statements.

These findings confirm the target of HDAC inhibitors that Repligen is developing for the treatment of inherited neurodegenerative diseases such as Friedreich’s ataxia. Study entitled study, entitled ‘Chemical Probes Identify a Role for Histone Deacetylase 3 in Friedreich’s Ataxia Gene Silencing ‘published today in the journal Chemistry & Biology was developed in collaboration with scientists at the Scripps Research Institute. – ‘Prior research has shown that HDAC enzymes play an important role in the silence, the gene involved in Friedreich’s ataxia,’stated Walter C.Dronedarone is priority review by by the U.S. Food and Drug Administration is issued and a registration dossier also under regulatory the European Medicines Agency .

Other articles from category "diagnostics":

Random articles